LXR as a therapeutic target for atherosclerosis

Lipids and Atherosclerosis

Volumn , Issue , 2005, Pages 93-100

  Schulman, I G ^a   Heyman, R A ^a  

^a EXELIXIS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84860555401     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (76)

1. Maglich JM, Sluder A, Guan X, et al. Comparison of complete nuclear receptor sets from the human, Caenorhabditis elegans and Drosophila genomes. Genome Biol 2001; 2: RESEARCH0029: 1-7
2. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell 1995; 83: 835-9
3. Steinmetz AC, Renaud JP, Moras D. Binding of ligands and activation of transcription by nuclear receptors. Annu Rev Biophys Biomol Struct 2001; 30: 329-59
4. Greschik H, Moras D. Structure-activity relationship of nuclear receptor-ligand interactions. Curr Top Med Chem 2003; 3: 1573-99
5. McKenna NJ, O’Malley BW. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 2002; 108: 465-74
6. Westin S, Rosenfeld MG, Glass CK. Nuclear receptor coactivators. Adv Pharmacol 2000; 47: 89-112
7. Yen PM. Physiological and molecular basis of thyroid hormone action. Physiol Rev 2001; 81: 1097-142
8. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002; 96: 23-43
9. Chawla A, Repa JJ, Evans RM, et al. Nuclear receptors and lipid physiology: opening the X-files. Science 2001; 294: 1866-70
10. Edwards PA, Kast HR, Anisfeld AM. BAREing it all. The adoption of lxr and fxr and their roles in lipid homeostasis. J Lipid Res 2002; 43: 2-12
11. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA 1997; 94: 4312-7
12. Kliewer SA, Sundseth SS, Jones SA, et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferatoractivated receptors alpha and gamma. Proc Natl Acad Sci USA 1997; 94: 4318-23
13. Lee CH, Olson P, Evans RM. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator- activated receptors. Endocrinology 2003; 144: 2201-7
14. Repa JJ, Mangelsdorf DJ. Nuclear receptor regulation of cholesterol and bile acid metabolism. Curr Opin Biotechnol 1999; 10: 557-63
15. Forman BM, Ruan B, Chen J, et al. The orphan nuclear receptor LXRalpha is positively and negatively regulated by distinct products of mevalonate metabolism. Proc Natl Acad Sci USA 1997; 94: 10588-93
16. Janowski BA, Grogan MJ, Jones SA, et al. Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta. Proc Natl Acad Sci USA 1999; 96: 266-71
17. Janowski BA, Willy PJ, Devi TR, et al. An oxysterol signalling pathway mediated by the nuclear receptor LXRα. Nature 1996; 383: 728-31
18. Lehmann JM, Kliewer SA, Moore LB, et al. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem 1997; 272: 3137-40
19. Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270: 12953-6
20. Forman BM, Tontonoz P, Chen J, et al. 15-Deoxydelta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995; 83: 803-12
21. Willy PJ, Umesono K, Ong ES, et al. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Devel 1995; 9: 1033-45
22. Shinar DM, Endo N, Rutledge SJ, et al. NER, a new member of the gene family encoding the human steroid hormone nuclear receptor. Gene 1994; 147: 273-6
23. Song C, Liao S. Cholestenoic acid is a naturally occurring ligand for liver X receptor alpha. Endocrinology 2000; 141: 4180-4
24. Fu X, Menke JG, Chen Y, et al. 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J Biol Chem 2001; 276: 38378-87
25. Peet DJ, Turley SD, Ma W, et al. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXRα. Cell 1998; 93: 693-704
26. Repa JJ, Berge KE, Pomajzl C, et al. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J Biol Chem 2002; 277: 18793-800
27. Berge KE, Tian H, Graf GA, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 2000; 290: 1771-5
28. Repa JJ, Liang G, Ou J, et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev 2000; 14: 2819-30
29. Schultz JR, Tu H, Luk A, et al. Role of LXRs in control of lipogenesis. Genes Dev 2000; 14: 2831-8
30. Zhang Y, Repa JJ, Gauthier K, et al. Regulation of lipoprotein lipase by the oxysterol receptors, LXRalpha and LXRbeta. J Biol Chem 2001; 276: 43018-24
31. Wang Y, Kurdi-Haidar B, Oram JF. LXR-mediated activation of macrophage stearoyl-CoA desaturase generates unsaturated fatty acids that destabilize ABCA1. J Lipid Res 2004; 45: 972-80
32. Joseph SB, Laffitte BA, Patel PH, et al. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by LXRs. J Biol Chem 2002; 277: 11019-25
33. Ou J, Tu H, Shan B, et al. Unsaturated fatty acids inhibit transcription of the sterol regulatory elementbinding protein-1c (SREBP-1c) gene by antagonizing ligand-dependent activation of the LXR. Proc Natl Acad Sci USA 2001; 98: 6027-32
34. Costet P, Luo Y, Wang N, et al. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem 2000; 275: 28240-5
35. Repa JJ, Turley SD, Lobaccaro JA, et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 2000; 289: 1524-9
36. Venkateswaran A, Laffitte BA, Joseph SB, et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc Natl Acad Sci USA 2000; 97: 12097-102
37. Hayden MR, Clee SM, Brooks-Wilson A, et al. Cholesterol efflux regulatory protein, Tangier disease and familial high-density lipoprotein deficiency. Curr Opin Lipidol 2000; 11: 117-22
38. Hobbs HH, Rader DJ. ABC1: connecting yellow tonsils, neuropathy, and very low HDL. J Clin Invest 1999; 104: 1015-17
39. Oram JF, Lawn RM. ABCA1. The gatekeeper for eliminating excess tissue cholesterol. J Lipid Res 2001; 42: 1173-9
40. Glass CK, Witztum JL. Atherosclerosis. The road ahead. Cell 2001; 104: 503-16
41. Aiello RJ, Brees D, Francone OL. ABCA1-deficient mice: insights into the role of monocyte lipid efflux in HDL formation and inflammation. Arterioscler Thromb Vasc Biol 2003; 23: 972-80
42. Singaraja RR, Fievet C, Castro G, et al. Increased ABCA1 activity protects against atherosclerosis. J Clin Invest 2002; 110: 35-42
43. Joyce CW, Amar MJ, Lambert G, et al. The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice. Proc Natl Acad Sci USA 2002; 99: 407-12
44. Wagner BL, Valledor AF, Shao G, et al. Promoterspecific roles for liver X receptor/corepressor complexes in the regulation of ABCA1 and SREBP1 gene expression. Mol Cell Biol 2003; 23: 5780-9
45. Kennedy MA, Venkateswaran A, Tarr PT, et al. Characterization of the human ABCG1 gene: liver X receptor activates an internal promoter that produces a novel transcript encoding an alternative form of the protein. J Biol Chem 2001; 276: 39438-47
46. Laffitte BA, Repa JJ, Joseph SB, et al. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc Natl Acad Sci USA 2001; 98: 507-12
47. Wang N, Lan D, Chen W, et al. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci USA 2004; 101: 9774-9
48. Schuster GU, Parini P, Wang L, et al. Accumulation of foam cells in liver X receptor-deficient mice. Circulation 2002; 106: 1147-53
49. Tangirala RK, Bischoff ED, Joseph SB, et al. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc Natl Acad Sci USA 2002; 99: 11896-901
50. Terasaka N, Hiroshima A, Koieyama T, et al. T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptordeficient mice. FEBS Lett 2003; 536: 6-11
51. Joseph SB, McKilligin E, Pei L, et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci USA 2002; 99: 7604-9
52. Lenin N, Bischoff ED, Daige Dl et al. Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists. Arterioscler Thromb Vasc Biol 2005; 25(1): 135-42
53. Fowler AJ, Sheu MY, Schmuth M, et al. Liver X receptor activators display anti-inflammatory activity in irritant and allergic contact dermatitis models: liver-X-receptor-specific inhibition of inflammation and primary cytokine production. J Invest Dermatol 2003; 120: 246-55
54. Joseph SB, Castrillo A, Laffitte BA, et al. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 2003; 9: 213-9
55. Miner JN. Designer glucocorticoids. Biochem Pharmacol 2002; 64: 355-61
56. Coghlan MJ, Jacobson PB, Lane B, et al. A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects. Mol Endocrinol 2003; 17: 860-9
57. Buja LM. Does atherosclerosis have an infectious etiology? Circulation 1996; 94: 872-3
58. Edfeldt K, Swedenborg J, Hansson GK, et al. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002; 105: 1158-61
59. Castrillo A, Joseph SB, Vaidya SA, et al. Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol Cell 2003; 12: 805-16
60. Laffitte BA, Chao LC, Li J, et al. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci USA 2003; 100: 5419-24
61. Cao G, Liang Y, Broderick CL, et al. Antidiabetic action of a liver x receptor agonist mediated by inhibition of hepatic gluconeogenesis. J Biol Chem 2003; 278: 1131-6
62. Muscat GE, Wagner BL, Hou J, et al. Regulation of cholesterol homeostasis and lipid metabolism in skeletal muscle by liver X receptors. J Biol Chem 2002; 277: 40722-8
63. Luo Y, Tall AR. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J Clin Invest 2000; 105: 513-20
64. de Grooth GJ, Smilde TJ, Van Wissen S, et al. The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia. Atherosclerosis 2004; 173: 261-7
65. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004; 350: 1505-15
66. Klerkx AH, de Grooth GJ, Zwinderman AH, et al. Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS). Eur J Clin Invest 2004; 34: 21-8
67. Alberti S, Schuster G, Parini P, et al. Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRbeta-deficient mice. J Clin Invest 2001; 107: 565-73
68. Lund EG, Menke JG, Sparrow CP. Liver X receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23: 1169-77
69. Hoerer S, Schmid A, Heckel A, et al. Crystal structure of the human liver X receptor beta ligand-binding domain in complex with a synthetic agonist. J Mol Biol 2003; 334: 853-61
70. Farnegardh M, Bonn T, Sun S, et al. The three-dimensional structure of the liver X receptor beta reveals a flexible ligand-binding pocket that can accommodate fundamentally different ligands. J Biol Chem 2003; 278: 38821-8
71. Williams S, Bledsoe RK, Collins JL, et al. X-ray crystal structure of the liver X receptor beta ligand binding domain: regulation by a histidine-tryptophan switch. J Biol Chem 2003; 278: 27138-43
72. Svensson S, Ostberg T, Jacobsson M, et al. Crystal structure of the heterodimeric complex of LXRalpha and RXRbeta ligand-binding domains in a fully agonistic conformation. Embo J 2003; 22: 4625-33
73. McDonnell DP, Connor CE, Wijayaratne A, et al. Definition of the molecular and cellular mechanisms underlying the tissue-selective agonist/antagonist activities of selective estrogen receptor modulators. Recent Prog Horm Res 2002; 57: 295-316
74. Oberfield JL, Collins JL, Holmes CP, et al. A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. Proc Natl Acad Sci USA 1999; 96: 6102-6
75. Rocchi S, Picard F, Vamecq J, et al. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell 2002; 8: 737-47
76. Schulman IG, Heyman RA. The flip side: identifying small molecule regulators of nuclear receptors. Chem Biol 2004; 11: 639-46